Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;22(1):59-69.
doi: 10.1007/s12311-022-01369-5. Epub 2022 Jan 27.

AARS2-Related Leukodystrophy: a Case Report and Literature Review

Affiliations
Review

AARS2-Related Leukodystrophy: a Case Report and Literature Review

Xiao Zhang et al. Cerebellum. 2023 Feb.

Abstract

Mutations in the alanyl-transfer RNA synthase 2 (AARS2) represent a heterogenous group of autosomal recessive leukodystrophy characterized by cognitive decline, ataxia, spasticity, and Parkinsonism. AARS2-related leukodystrophy (AARS2-L) is extremely rare. To date, only 45 genetically confirmed cases, explaining the frequent diagnostic delay. Here, we report a 21-year-old male presented with unsteady gait and weakness in the bilateral lower extremities. Examination revealed dysarthria, cerebellar ataxia, paraparesis, and Parkinsonism with generalized hyperreflexia. MRI findings showed extensive white matter lesions in bilateral frontoparietal lobes, immediate periventricular regions, and corpus callosum. Focused exome sequencing revealed compound heterozygous mutations in the AARS2 gene confirming the diagnosis of AARS2-L; two heterogeneous missense mutations (c.452 T > C, p. M151T; c. 2557C > T, p. R853W) appeared together for the first time. We also reviewed phenotypic spectra of AARS2-related leukodystrophies from a total of 45 reported cases.

Keywords: Alanyl-transfer RNA synthase 2 (AARS2); Axonal spheroids and pigmented glia (ALSP); Clinical features; Gene mutation; Leukodystrophy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Vanderver A, et al. Case definition and classification of leukodystrophies and leukoencephalopathies. Mol Genet Metab. 2015;114:494–500. https://doi.org/10.1016/j.ymgme.2015.01.006 . - DOI
    1. Parikh S, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015;114:501–15. https://doi.org/10.1016/j.ymgme.2014.12.434 . - DOI
    1. Renaud D. Inherited leukoencephalopathies. Semin Neurol. 2012;32:3–8. https://doi.org/10.1055/s-0032-1306380 . - DOI
    1. Euro L, et al. Structural modeling of tissue-specific mitochondrial alanyl-tRNA synthetase (AARS2) defects predicts differential effects on aminoacylation. Front Genet. 2015;6:21. https://doi.org/10.3389/fgene.2015.00021 . - DOI
    1. Dallabona C, et al. Novel (ovario) leukodystrophy related to AARS2 mutations. Neurology. 2014;82:2063–71. https://doi.org/10.1212/wnl.0000000000000497 . - DOI

LinkOut - more resources